Compare Canopy Growth Corp (CGC) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Teradyne, Inc. — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Teradyne, Inc. trades at $405.96 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 140.9× Canopy Growth Corp's market cap, and Teradyne, Inc. pays a 0.14% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | TER | |
|---|---|---|
Market Cap | $421.10M | $59.34B |
Sector | Health | Technology |
52-Week High | $1.92 | $483.84 |
52-Week Low | $0.86 | $109.30 |
Enterprise Value | $378.55M | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Teradyne (TER) trades at $365.10, down 3.75% on the day despite strong Q2 2026 earnings that beat expectations with EPS of $2.47 versus $2.09 forecast. The stock shows neutral technical signals with support at $358 and resistance at $380, while fundamentals remain robust with 25.77% net margins and 36.66% ROE. Recent news highlights AI-driven semiconductor test demand fueling record revenues.
Outlook remains positive with analyst consensus price target of $481.63 (32% upside) and no sell ratings. Key risks include premium valuation (P/E 52.14) and dependence on semiconductor cycle volatility. Strong institutional ownership and consistent earnings beats support bullish sentiment for long-term growth in AI and robotics markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
